Fig. 4From: RIVA – a phase IIa study of rituximab and varlilumab in relapsed or refractory B-cell malignancies: study protocol for a randomized controlled trialScreening and randomisation. CT computed tomography, ECG electrocardiogram, Exc exclusion, Hep hepatitis, HIV human immunodeficiency virus, Inc inclusion, PET positron emission tomographyBack to article page